Resveratrol antagonizes EGFR-dependent Erk1/2 activation in human androgen-independent prostate cancer cells with associated isozyme-selective PKCα inhibition

Investigational New Drugs

Volumn 22, Issue 2, 2004, Pages 107-117

  Stewart, Jubilee R ^a   O'Brian, Catherine A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Epidermal growth factor receptor; Erk1 2, androgen independent prostate cancer; Protein kinase C alpha (PKC ); Resveratrol

Indexed keywords

ANDROGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; ISOENZYME; MITOGEN ACTIVATED PROTEIN KINASE 1; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C ALPHA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C IOTA; PROTEIN KINASE C MU; PROTEIN KINASE C ZETA; RESVERATROL; TRANSFORMING GROWTH FACTOR ALPHA RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHOSPHORYLATION; CANCER CELL; CANCER CELL CULTURE; CELL LYSATE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOSKELETON; DRUG EFFECT; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANDROGENS; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME INHIBITORS; HUMANS; ISOENZYMES; MALE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PROSTATIC NEOPLASMS; PROTEIN KINASE C; PROTEIN KINASE C-ALPHA; RECEPTOR, EPIDERMAL GROWTH FACTOR; STILBENES;

EID: 1442326130     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:DRUG.0000011787.75522.ec     Document Type: Article

References (45)

1. Yang CS, Landau JM, Huang M-T, Newmark HL: Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr 21: 381-406, 2001
2. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CWW, Fong HHS, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275: 218-220, 1997
3. Gusman J, Malonne H, Atassi G: A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 22: 1111-1117, 2001
4. Subbaramaiah K, Chung WJ, Michaluart P, Telang N, Tanabe T, Inoue H, Jang M, Pezzuto JM, Dannenberg AJ: Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. JBC 273: 21875-21882, 1998
5. Mutoh M, Takahashi M, Fukuda K, Matsushima-Hibiya Y, Hiroshi Mutoh H, Sugimura T, Wakabayashi K: Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis 21: 959-963, 2000
6. Sgambato A, Ardito R, Faraglia B, Boninsegna A, Wolf FI, Cittadini A: Resveratrol, a natural phenolic compound, inhibits cell proliferation and prevents oxidative DNA damage. Mutat Res 496: 171-180, 2001
7. Hsieh T-C, Wu JM: Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Exp Cell Res 249: 109-115, 1999
8. Schneider Y, Vincent F, Duranton B, Badolo L, Gossé F, Bergmann C, Seiler N, Raul F: Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 158: 85-91, 2000
9. Lara PN, Jr., Meyers FJ: Treatment options in androgen-independent prostate cancer. Cancer Inves 17: 137-144, 1999
10. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C: Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor alpha in the progression of prostatic neoplasms. Clin Cancer Res 1: 545-550, 1995
11. Jones HE, Eaton CL, Barrow D, Dutkowski CM, Gee JMW, Griffiths K: Comparative studies of the mitogenic effects of epidermal growth factor and transforming growth factor-and the expression of various growth factors in neoplastic and non-neoplastic prostatic cell lines. Prostate 30: 219-231, 1997
12. Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI, Goldstein NI: The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 19: 419-427, 1996
13. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM: Autonomous growth of androgen-independent human prostatic carcinoma cells: role of transforming growth factor alpha. Cancer Res 51: 2780-2785, 1991
14. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54: 5474-5478, 1994
15. Robinson MJ, Cobb MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9: 180-186, 1997
16. Putz T, Culig Z, Eder IE, Nessler-Menardi C, Bartsch G, Grunicke H, Überall F, Klocker H: Epidermal growth factor (EGF) receptor blockade inhibits the Action of EGF, insulin-like growth factor 1, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res 59: 227-233, 1999
17. Yeh S, Lin H-K, Kang H-Y, Thin TH, Lin M-F, Chang C: From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. PNAS 96: 5458-5463, 1999
18. Gioeli D, Mandell JW, Petroni GR, Frierson HF, Jr., Web MJ: Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res 59: 279-284, 1999
19. Price D, Rocca G, Gou C, Ballo M, Schwinn D, Luttrell L: Activation of extracellular signal-regulated kinase in human prostate cancer. J Urol 162: 1537-1542, 1999
20. Chen N, Ma W-Y, She Q-B, Wu E, Liu G, Bode AM, Dong Z: Transactivation of the epidermal growth factor receptor is involved in 12-O-Tetradecanoylphorbol-13-acetate-induced signal transduction. JBC 276: 46722-46728, 2001.
21. Newton AC: Regulation of protein kinase C. Cur Opin Cell Biol 9: 161-167, 1997
22. Stewart JR, Ward NE, Ioannides CG, O'Brian CA: Resveratrol preferentially inhibits protein kinase C-catalyzed phosphorylation of a cofactor-independent, arginine-rich protein substrate by a novel mechanism. Biochemistry 38: 13244-13251, 1999
23. Stewart JR, Christman KL, O'Brian CA: Effects of resveratrol on the autophosphorylation of phorbol ester-responsive protein kinases: inhibition of protein kinase D but not protein kinase C isozyme autophosphorylation. Biochem Pharmacol 60: 1355-1359, 2000
24. Ács P, Bögi K, Marquez AM, Bíró T, Szállási Z, Blumberg PM: The catalytic domain of protein kinase C chimeras modulates the affinity and targeting of phorbol ester-induced translocation. JBC 272: 22148-22153, 1997
25. Ogretmen B, Schady D, Usta J, Wood R, Kraveka JM, Luberto C, Birbes H, Hannun YA, Obeid LM: Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. JBC 276: 24901-24910, 2001
26. Gupta KP, Ward NE, Gravitt KR, Bergman PJ, O'Brian CA: Partial reversal of multidrug resistance in human breast cancer cells by an N-myristoylated protein kinase C-α pseudosubstrate peptide. JBC 271: 2102-2111, 1996
27. De Miguel P, Royuela, Bethencourt R, Ruiz, Fraile, Paniagua: Immunohistochemical comparative analysis of transforming growth factor, epidermal growth factor, and epidermal growth factor receptor in normal, hyperplastic and neoplastic human prostates. Cytokine 11: 722-727, 1999
28. Gou C, Luttrell L, Price D: Mitogenic signaling in androgen sensitive and insensitive prostate cancer cell lines. J Urol 163: 1027-1032, 2000
29. Payne DM, Rossomando AJ, Martino P, Erickson AK, Her JH, Shabanowitz J, Hunt DF, Weber MJ, Sturgill TW: Identification of the regulatory phosphorylation sites in pp42/mitogen-activated protein kinase (MAP kinase). EMBO J 10: 885-892, 1991
30. Sturgill TW et al.: Nature 334: 715-718, 1988
31. Kolch W, Heldecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D, Rapp UR: Protein kinase C activates RAF-1 by direct phosphorylation. Nature 364:249-252, 1993
32. Miranti CK, Ohno S, Brugge JS: Protein kinase C regulates integrin-induced activation of the extracellular regulated kinase pathway upstream of Shc. JBC 274: 10571-10581, 1999
33. Comford P, Evans J, Dodson A, Parsons K, Woolfenden A, Neoptolemos J, Foster CS: Protein kinase C isoenzyme patterns characteristically modulated in early prostate cancer. Am J Pathol 154: 137-144, 1999
34. Ron D, Kazanietz M: New insights into the regulation of protein kinase C and novel phorbol ester receptors. FASEB J 13: 1658-1676, 1999
35. Matthews SA, Rozengurt E, Cantrell D: Characterization of serine 916 as an in vivo autophosphorylation site for protein kinase D/protein kinase Cμ. JBC 274: 26543-26549, 1999
36. Vertommen D, Rider M, Ni Y, Waelkens E, Merlevede W, Vandenheede JR, Van Lint J: Regulation of protein kinase D by multisite phosphorylation: identification of phosphorylation sites by mass spectrometry and characterization by site-directed mutagenesis. JBC 275: 19567-19576, 2000
37. 1-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 Cells. Clin Cancer Res 7: 1466-1473, 2001
38. Mouria M, Gukovskaya AS, Jung Y, Buechler P, Hines OJ, Reber HA, Pandol SJ: Food-derived polyphenols inhibit pancreatic cancer growth through mitochondrial cytochrome C release and apoptosis. Int J Cancer 98: 761-769, 2002.
39. Gehm BD, McAndrews JM, Chien P-Y, Jameson JL: Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. PNAS 94: 14138-14143, 1997
40. Bhat KPL, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM: Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res 61: 7456-7463, 2001
41. Mgbonyebi OP, Russo J, Russo IH: Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol 12: 865-869, 1998
42. Mitchell SH, Zhu W, Young CYF: Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res 59: 5892-5895, 1999
43. Logothetis CJ: Docetaxel in the integrated management of prostate cancer. Current applications and future promise. Oncology 16: 63-72, 2002
44. Karashima T, Sweeney P, Slaton JW, Kim SJ, Kedar D, Izawa JI, Fan Z, Pettaway C, Hicklin DJ, Shuin T, Dinney CP: Inhibition of angiogenesis by the antiepidermal growth factor receptor antibody ImClone C225 in androgen-independent prostate cancer growing orthotopically in nude mice. Clin Cancer Res 8: 1253-1264, 2002.
45. Siromak FM, Zakowski MF, Miller VA, Scher HI, Kris MG, Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6: 4885-4892, 2000